Holocene Advisors
DFTX

Holocene Advisors’s Definium Therapeutics DFTX Stock Holding History

Holocene Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5M Sell
796,574
-295,393
-27% -$7.3M 0.08% 226
2026
Q1 		$20.6M Buy
+1,091,967
New +$18.5M 0.05% 262

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Holocene Advisors's DFTX Position: Q2 2026 in Review

Holocene Advisors reduced its Definium Therapeutics (DFTX) stake by 27% in Q2 2026, selling an estimated $7.3M and leaving 796,574 shares worth $37.5M. The position accounts for 0.08% of the portfolio, ranked #226.

Holocene Advisors first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Holocene Advisors held 796,574 shares of Definium Therapeutics worth $37.5M as of Q2 2026.
  • Holocene Advisors sold 295,393 Definium Therapeutics shares in Q2 2026, an estimated $7.3M.
  • Definium Therapeutics made up 0.08% of Holocene Advisors's portfolio in Q2 2026, its #226 holding.
  • Holocene Advisors first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.